Bexicaserin
Sponsors
Longboard Pharmaceuticals Inc.
Conditions
Developmental and Epileptic Encephalopathies (DEE)Developmental and Epileptic Encephalopathies (DEEs)Dravet Syndrome
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome
RecruitingCTIS2024-514937-39-00
Start: 2025-05-20Target: 93Updated: 2026-01-26
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Developmental and
Epileptic Encephalopathies
RecruitingCTIS2024-516412-17-00
Start: 2025-08-26Target: 102Updated: 2025-08-18
A Phase 3, Open-Label Study to Investigate the Long-Term Safety and Efficacy of LP352 in the Treatment of Seizures in Children and Adults with Developmental and Epileptic Encephalopathy
RecruitingCTIS2024-514974-39-00
Start: 2025-10-10Target: 175Updated: 2025-08-19